Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Danish (OMX) Healthcare Sector Analysis

UpdatedMay 01, 2026
DataAggregated Company Financials
Companies20
  • 7D6.8%
  • 3M-23.8%
  • 1Y-33.8%
  • YTD-17.4%

The Healthcare is pretty flat in the last 7 days, but Novo Nordisk has stood out, gaining 10%. Unfortunately though, the industry is down 36% over the past 12 months. As for the next few years, earnings are expected to grow by 3.5% per annum.

Sector Valuation and Performance

Has the Danish Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Fri, 01 May 2026DKK 1.6tDKK 447.4bDKK 129.9b18x12.4x3.6x
Sun, 29 Mar 2026DKK 1.4tDKK 447.8bDKK 130.1b16.6x10.9x3.2x
Tue, 24 Feb 2026DKK 1.6tDKK 447.7bDKK 131.0b18.5x11.8x3.5x
Thu, 22 Jan 2026DKK 2.2tDKK 453.9bDKK 136.9b18.3x15.7x4.7x
Sat, 20 Dec 2025DKK 1.9tDKK 453.8bDKK 136.9b16.9x13.7x4.1x
Mon, 17 Nov 2025DKK 1.9tDKK 454.1bDKK 137.0b17.4x13.8x4.2x
Wed, 15 Oct 2025DKK 2.1tDKK 447.7bDKK 141.8b17.9x14.9x4.7x
Fri, 12 Sep 2025DKK 2.0tDKK 447.3bDKK 141.6b19.8x14.3x4.5x
Sun, 10 Aug 2025DKK 1.9tDKK 434.8bDKK 132.5b28.7x14.2x4.3x
Tue, 08 Jul 2025DKK 2.4tDKK 423.0bDKK 124.5b30.4x19.3x5.7x
Thu, 05 Jun 2025DKK 2.6tDKK 423.7bDKK 124.7b30.8x20.7x6.1x
Sat, 03 May 2025DKK 2.5tDKK 409.3bDKK 121.3b23x20.6x6.1x
Mon, 31 Mar 2025DKK 2.6tDKK 409.5bDKK 121.3b22.8x21.3x6.3x
Wed, 26 Feb 2025DKK 3.5tDKK 410.0bDKK 121.4b29.2x28.6x8.5x
Fri, 24 Jan 2025DKK 3.1tDKK 387.4bDKK 111.3b28.6x28.2x8.1x
Sun, 22 Dec 2024DKK 3.1tDKK 387.4bDKK 111.3b28.7x28.2x8.1x
Tue, 19 Nov 2024DKK 3.7tDKK 387.3bDKK 111.3b31.3x33.1x9.5x
Thu, 17 Oct 2024DKK 4.1tDKK 372.1bDKK 107.2b37.1x38.6x11.1x
Sat, 14 Sep 2024DKK 4.7tDKK 372.0bDKK 107.1b36x43.8x12.6x
Mon, 12 Aug 2024DKK 4.7tDKK 370.3bDKK 107.0b35.9x43.6x12.6x
Wed, 10 Jul 2024DKK 4.9tDKK 355.3bDKK 106.2b35.4x45.9x13.7x
Fri, 07 Jun 2024DKK 4.9tDKK 355.2bDKK 106.2b36.3x46x13.8x
Sun, 05 May 2024DKK 4.3tDKK 354.8bDKK 106.4b33.9x40.9x12.3x
Tue, 02 Apr 2024DKK 4.5tDKK 341.2bDKK 99.6b39.2x45.4x13.3x
Thu, 29 Feb 2024DKK 4.3tDKK 340.0bDKK 98.9b37.4x43.5x12.6x
Sat, 27 Jan 2024DKK 3.8tDKK 320.5bDKK 90.0b34.7x42x11.8x
Mon, 25 Dec 2023DKK 3.6tDKK 320.4bDKK 90.0b32.8x40.2x11.3x
Wed, 22 Nov 2023DKK 3.6tDKK 320.4bDKK 90.0b32.6x40.3x11.3x
Fri, 20 Oct 2023DKK 3.5tDKK 305.5bDKK 82.2b27.7x42.9x11.5x
Sun, 17 Sep 2023DKK 3.5tDKK 305.5bDKK 82.2b36.6x42.9x11.5x
Tue, 15 Aug 2023DKK 3.3tDKK 301.3bDKK 81.0b40.7x40.7x11x
Thu, 13 Jul 2023DKK 2.8tDKK 287.0bDKK 75.4b37.9x37.7x9.9x
Sat, 10 Jun 2023DKK 3.0tDKK 287.1bDKK 75.5b40x39.9x10.5x
Mon, 08 May 2023DKK 3.0tDKK 284.0bDKK 74.5b39.3x40.8x10.7x
Price to Earnings Ratio

40.8x


Total Market Cap: DKK 3.0tTotal Earnings: DKK 74.5bTotal Revenue: DKK 284.0bTotal Market Cap vs Earnings and Revenue0%0%0%
Danish Healthcare Sector Price to Earnings3Y Average 30.9x202420252026
Current Industry PE
  • Investors are pessimistic on the Danish Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 11.8x which is lower than its 3-year average PE of 31.0x.
  • The 3-year average PS ratio of 8.9x is higher than the industry's current PS ratio of 3.4x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have grown 20% per year over the last three years.
  • Revenues for these companies have grown 16% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Danish Healthcare sector?

DK Market2.59%
Healthcare6.84%
Pharma9.78%
Healthtech0.41%
Biotech-2.55%
Life Sciences-2.55%
Healthcare Services-4.71%
Medical Equipment-5.22%
Industry PE
  • Investors are most optimistic about the Healthcare Services industry which is trading above its 3-year average PE ratio of 593x.
    • Analysts are expecting annual earnings growth of 87.6%, which is higher than its past year's earnings decline of 99.7% per year.
Forecasted Growth
  • Analysts are most optimistic on the Healthcare Services industry, expecting annual earnings growth of 88% over the next 5 years.
  • This is better than its past earnings decline of 100% per year.
  • In contrast, the Life Sciences industry is expected to see its earnings decline by 8.8% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
NOVO B Novo NordiskDKK 272.2510.4%
+DKK 112.7b		-38.7%PE11.8x
ALK B ALK-AbellóDKK 238.405.9%
+DKK 2.9b		55.6%PE44.1x
BIOPOR BioPortoDKK 1.1321.0%
+DKK 97.0m		-27.8%PS13.9x
NNIT NNITDKK 44.200.5%
+DKK 5.0m		-38.2%PS0.6x
PEG Pharma Equity GroupDKK 0.0854.4%
+DKK 4.4m		4.0%PB4.1x

Latest News

PEG
DKK 0.085
Pharma Equity Group
7D
4.4%
1Y
4.0%
EMBLA
DKK 26.30
Embla Medical hf
7D
-5.7%
1Y
-12.8%

EMBLA: Share Cancellations And Capital Authorisations Will Support Future Upside

Analysts have trimmed their price target on Embla Medical hf. to DKK 33.30 from DKK 37.40, citing updated assumptions around a slightly higher discount rate, more moderate revenue growth of 8.40% and a lower future P/E of about 21x, while keeping profit margin expectations broadly in line.
ZEAL
DKK 299.40
Zealand Pharma
7D
-1.9%
1Y
-35.8%
COLO B
DKK 393.90
Coloplast
7D
-6.3%
1Y
-44.2%
GMAB
DKK 1,690.00
Genmab
7D
-3.1%
1Y
20.8%

GMAB: 2026 Pipeline Catalysts Will Test Balanced Risk And Opportunity Outlook

Narrative Update on Genmab The updated analyst framework lifts Genmab's fair value estimate from DKK 1,300 to about DKK 1,588. This reflects higher assumed revenue growth and P/E multiples as analysts factor in recent upgrades, resumed coverage and new acquisition driven pipeline contributions.
GUBRA
DKK 317.40
Gubra
7D
-3.1%
1Y
-17.6%
ALK B
DKK 238.40
ALK-Abelló
7D
5.9%
1Y
55.6%
DEMANT
DKK 202.00
Demant
7D
-3.0%
1Y
-14.6%

DEMANT: 2026 EBIT Guidance May Support Re Rating Despite Mixed Research

Analysts have adjusted their price target for Demant slightly lower to DKK 229.83 from DKK 232.44. This reflects a mix of recent target increases and cuts across major banks, as well as a modest recalibration of fair value, discount rate, revenue growth, profit margin and future P/E assumptions.
NOVO B
DKK 272.25
Novo Nordisk
7D
10.4%
1Y
-38.7%
AMBU B
DKK 63.05
Ambu
7D
-4.7%
1Y
-45.9%

AMBU B: Reset P/E Assumptions Will Support Future Upside Repricing

Ambu's analyst price target has been reduced by DKK 12 to reflect updated views on its P/E assumptions, revenue growth profile and profitability, with analysts pointing to the recent DKK 12 target cut cited in Street research. Analyst Commentary JPMorgan's DKK 12 reduction in its Ambu price target reflects a reset of P/E expectations and a more cautious stance on the company's revenue growth and profitability profile.
HLUN B
DKK 42.88
H. Lundbeck
7D
-0.8%
1Y
35.9%

HLUN B: Dividend Policy And Neuroscience Pipeline Will Support Balanced Medium Term Outlook

Analysts have kept their DKK 46.13 price target for H. Lundbeck unchanged, citing consistent assumptions about revenue growth, profit margins and future P/E as the basis for their view.
BIOPOR
DKK 1.13
BioPorto
7D
21.0%
1Y
-27.8%
STENO
DKK 1.12
Stenocare
7D
9.8%
1Y
182.1%
NNIT
DKK 44.20
NNIT
7D
0.5%
1Y
-38.2%